Throughout the Etiologic and Early Marker Studies (EEMS) existence, several studies have measured various sex hormones in blood serum. For CDAS, these measurements are available in separate datasets corresponding to each study for which they were originally selected.
These studies were each selected at different time points, using a different set of exclusions and matching criteria. For all studies, the common requirements for inclusion were etiologic consent, serum availability, intervention arm, a baseline questionnaire, some form of follow-up within the trial, and no history of the site-specific cancer prior to blood collection. All studies used blood collected at T0, except for the upper GI study and 2nd endometrial study, where the first available pre-diagnostic collection was used. For all studies except for breast and prostate, the set of cases were matched directly to the controls. For breast and prostate, however, the populations were the subsets of the Breast and Prostate Cancer Cohort Consortium (BPC3) study and the Cancer Genetic Markers of Susceptibility (CGEMS) study who had available serum.
|Site||Non-Common Inclusion Criteria||Matching Variables||Cases||Non-Cases|
Below is a table of the analytes measured in each study.
|Prostate||Breast||Endometrial||2nd Prostate||2nd Endometrial||Upper GI|
|Sex Hormone-Binding Globulin||X||X|
Sex Hormones data can be obtained in the Sex Hormones datasets
Endogenous sex hormones and the risk of prostate cancer: a prospective study.
Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB
Int. J. Cancer. 2008 May; Volume 122 (Issue 10): Pages 2345-50 PUBMED
Estrogen metabolism and risk of breast cancer in postmenopausal women.
Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD, Berg CD, Hoover RN, Ziegler RG
J. Natl. Cancer Inst. 2012 Feb; Volume 104 (Issue 4): Pages 326-39 PUBMED
Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Luhn P, Dallal CM, Weiss JM, Black A, Huang WY, Lacey JV, Hayes RB, Stanczyk FZ, Wentzensen N, Brinton LA
Cancer Epidemiol. Biomarkers Prev. 2013 Jul; Volume 22 (Issue 7): Pages 1304-12 PUBMED
Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.
Black A, Pinsky PF, Grubb RL, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB
Cancer Epidemiol. Biomarkers Prev. 2014 Nov; Volume 23 (Issue 11): Pages 2374-82 PUBMED
Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N
Int. J. Cancer. 2017 Feb; Volume 140 (Issue 3): Pages 600-610 PUBMED
Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men.
Petrick JL, Hyland PL, Caron P, Falk RT, Pfeiffer RM, Dawsey SM, Abnet CC, Taylor PR, Weinstein SJ, Albanes D, Freedman ND, Gapstur SM, Bradwin G, Guillemette C, Campbell PT, Cook MB
J. Natl. Cancer Inst. 2018 May PUBMED